（一） 股东会召开的时间：2026 年 3 月 31 日 （二） 股东会召开的地点：上海市闵行区华西路 680 号（圣湘生物上海产业园） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688289 证券简称：圣湘生物 公告编号：2026-007 圣湘生物科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 307 | | --- | --- | | 普通股股东人数 | 307 | | 2、出席会议的股东所持有的表决权数量 | 56,971,929 | | 普通股股东所持有表决权数量 | 56,971,929 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 9.9105 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 9.9105 | （四） 表决 ...

关于 圣湘生物科技股份有限公司 2026年第一次临时股东会的 法律意见书 二〇二六年三月三十一日 湖南省长沙市建湘路 393 号世茂环球金融中心 63 层 410000 深圳市福田区金田路 4028 号荣超经贸中心 1606 518038 上海市闵行区申贵路 669 号 1 楼 105 室 201100 网站：www.qiyuan.com 致：圣湘生物科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受圣湘生物科技股份有限公司 （以下简称"公司"）的委托，指派本所律师出席了公司 2026 年第一次临时股东 会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人 员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发 表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《圣 湘生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 本所声明如下： （一）在本法律意见书中，本 ...

圣湘生物科技股份有限公司（688289）2026 年第一次临时股东会会议资料 目录 | 2026 年第一次临时股东会会议须知 | 2 | | --- | --- | | 年第一次临时股东会会议议程 2026 | 4 | | 议案一：圣湘生物科技股份有限公司关于与关联方共同投资华斯无微生物科技 | | | （深圳）有限公司的议案 | 6 | 1 圣湘生物科技股份有限公司（688289）2026 年第一次临时股东会会议资料 圣湘生物科技股份有限公司 2026 年第一次临时股东会会议资料 二〇二六年三月 五、股东及股东代理人要求发言时，不得打断会议报告人的报告或其他股东 及股东代理人的发言。在股东会进行表决时，股东及股东代理人不再进行发言。 股东及股东代理人违反上述规定，会议主持人有权加以拒绝或制止。 六、主持人可安排公司董事、高级管理人员回答股东所提问题。对于可能将 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》以 ...

Group 1 - Haier and other companies have responded to being named in the CCTV "3.15" gala, with Haier expressing apologies and confirming compliance with national standards by limiting electric vehicle speeds to 25 km/h [3] - Apple announced a reduction in the commission rate for its App Store in China, lowering the standard rate from 30% to 25% and for eligible small developers from 15% to 12% [3] - Meta plans to conduct large-scale layoffs involving 20% or more of its workforce to offset high AI infrastructure costs and has delayed the release of its AI model "Avocado" due to performance issues compared to competitors [4] Group 2 - Tencent Cloud will provide free installation and deployment services for its products across 17 cities in China over the next 40 days [7] - Didi's core platform is projected to see a 13.5% year-on-year increase in order volume by Q4 2025, reaching 4.844 billion orders, with a total transaction value of 123.8 billion yuan [8] - China Power Construction signed a contract for a nickel mining project in Indonesia worth approximately 54.56 billion yuan, with a contract duration of 60 months [8] Group 3 - Amazon has partnered with AI chip startup Cerebras Systems to enhance AI computing efficiency and accelerate the development of various AI applications [11] - Nvidia's GTC 2026 technology conference will focus on AI factories and the next-generation M10 chip, with supply chain implications for related industries [11] - Tesla's CEO announced the launch of the AI chip super factory Terafab, aiming for an annual production capacity of 100 to 200 billion chips [11] Group 4 - Samsung has raised foundry fees and is developing new HBM4E memory using a 2nm process, which is ahead of the industry standard [14] - Toyota's new RAV4 model has been launched, but market feedback is cautious regarding its sales without price incentives [15] - Japan Post has agreed to acquire a Norwegian shipping company to strengthen its global network and expand its participation in niche markets [15]

Financial Insights - The A-share market shows resilience, with a focus on dividend stocks as a potential investment direction [4][6] - The overall A-share index fell by 0.94%, closing at 6750.45 points, with the Shanghai Composite Index down 0.82% at 4095.45 points [6][7] - The market is experiencing a shift from technology-focused investments to dividend-oriented strategies due to increased geopolitical tensions and economic uncertainties [6][8] Company Dynamics - Eddie Pharmaceuticals (688488.SH) received approval for the drug registration of Dolutegravir Sodium Tablets, which will enhance its product offerings in the HIV treatment sector [36] - Shenzhen South Circuit (002916.SZ) reported a revenue of 23.647 billion yuan for 2025, marking a year-on-year growth of 32.05%, with a net profit increase of 74.47% [39][40] - Victory Technology (300476.SZ) achieved a revenue of 19.292 billion yuan in 2025, reflecting a significant year-on-year growth of 79.77%, with net profit soaring by 273.52% [42] Industry Trends - China joined the "Triple Nuclear Energy Declaration," aiming to enhance global nuclear energy sustainability and support low-carbon transitions [32][33] - Apple announced a reduction in the App Store commission rate in mainland China from 30% to 25%, effective March 15, 2026, which may impact the app development ecosystem [34][35]

证券代码：688289 证券简称：圣湘生物 公告编号：2026-005 圣湘生物科技股份有限公司 关于与关联方共同投资华斯无微生物科技（深 圳）有限公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）拟与关联 方湖南金芙蓉圣湘生物股权投资基金合伙企业（有限合伙）（以下简称"基金"） 共同投资设立湖南圣维华斯生物技术有限公司（拟定名，具体名称以工商登记部 门核准名称为准，以下简称"合资公司"或"圣维华斯"），并将其作为后续收 购华斯无微生物科技（深圳）有限公司（以下简称"华斯无微"）100%股权的 投资主体。其中，公司以自有资金合计出资人民币 6,543.80 万元，本次交易完成 后，合资公司及华斯无微将纳入公司合并报表范围。 本次交易系与关联方共同投资，构成关联交易，未构成《上市公司重大 资产重组管理办法》规定的重大资产重组。 本次交易实施不存在重大法律障碍。 本次交易事项已经公司第三届董事会 2026 年第二次临时会议及第三届 董事会独立董 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2026-006 圣湘生物科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 召开地点：上海市闵行区华西路 680 号（圣湘生物上海产业园） （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 31 日 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 3 月 31 日 14 点 30 分 至2026 年 3 月 31 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年3月31日 本次股东会采用的网络投票系统 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2026-004 圣湘生物科技股份有限公司 关于与关联方共同投资北京哲源科技有限责 任公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）拟与关联 方湖南金芙蓉圣湘生物股权投资基金合伙企业（有限合伙）（以下简称"基金"） 共同投资北京哲源科技有限责任公司（以下简称"哲源科技"），其中，公司将 以自有资金投资 4,000.00 万元，基金将投资 5,000.00 万元，通过受让股权及增资 交易后，公司将持有哲源科技 4.02%的股权，基金将持有哲源科技 5.02%的股权。 本次交易系与关联方共同投资，构成关联交易，未构成《上市公司重大 资产重组管理办法》规定的重大资产重组。 本次交易实施不存在重大法律障碍。 本次交易事项已经公司第三届董事会 2026 年第一次临时会议及第三届 董事会独立董事专门会议 2026 年第一次会议审议通过，关联董事戴立忠先生已 回避表决。本事项无需提交公司股东会审议 ...

Core Viewpoint - The article discusses the ongoing reforms in China's medical procurement and price governance, emphasizing the need for optimization to balance cost control and innovation in the healthcare sector [3]. Group 1: Medical Procurement and Price Governance - The government work report highlights the optimization of centralized medical procurement and price governance, aiming to deepen the reform of medical insurance payment methods and improve the use of surplus funds [3]. - The "volume-based procurement" mechanism has significantly reduced price margins in the medical supply chain, prompting discussions on further optimization among representatives at the National People's Congress [3]. - The implementation of volume-based procurement has accelerated the process of domestic substitution, effectively lowering patient burdens and regulating market competition [3]. Group 2: Challenges and Recommendations - Challenges such as protecting historical volumes and malicious low-price competition remain in the execution of procurement policies, necessitating adjustments to reporting rules and price constraints [4]. - Suggestions include optimizing procurement reporting rules to balance efficiency and market innovation, and establishing a mechanism to curb malicious low-price competition [4]. - A recommendation was made to create a balance between cost control and innovation, proposing differentiated medical insurance payment policies and an "innovation technology exemption channel" for high-value diagnostic projects [4]. Group 3: Payment Mechanism and Innovation - Concerns were raised about the disconnect between procurement and payment, where high-priced generic and original drugs still enjoy high medical insurance payment standards despite not being selected in procurement [5]. - A proposal was made to establish a direct linkage mechanism between procurement prices and medical insurance payment standards, ensuring that selected drugs have their prices reflected in payment standards [5]. - The National Medical Insurance Administration has redirected savings from procurement to pay for clinically valuable innovative drugs, encouraging pharmaceutical companies to invest in research and development [5]. Group 4: Strategic Purchasing and Negotiation Mechanism - Suggestions were made to enhance the strategic purchasing of innovative products by the medical insurance fund, expanding the coverage of innovative drugs while maintaining basic insurance [6]. - The negotiation mechanism for including drugs in the medical insurance directory needs optimization to better reflect the value of innovative drugs and align domestic and international pricing [7]. - It was recommended to consider multiple factors in negotiations to ensure reasonable pricing and innovation returns, potentially allowing for a window of autonomous pricing to stabilize market expectations [8].

Group 1 - The core viewpoint of the article is that Shengxiang Bio announced its financial performance for 2025, projecting a total operating revenue of 1.648 billion yuan, which represents a year-on-year growth of 13.04% [2] - The net profit attributable to shareholders of the listed company is expected to be 198 million yuan [2]